Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models

• Main Authors: Sujatha Kumar (Author), Srimoyee Ghosh (Author), Geeta Sharma (Author), Zebin Wang (Author), Marilyn R. Kehry (Author), Margaret H. Marino (Author), Tamlyn Y. Neben (Author), Sharon Lu (Author), Shouqi Luo (Author), Simon Roberts (Author), Sridhar Ramaswamy (Author), Hadi Danaee (Author), David Jenkins (Author)
• Formato: Livro
• Publicado em: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Inhibitors of programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have dramatically changed the treatment landscape for patients with cancer. Clinical activity of anti-PD-(L)1 antibodies has resulted in increased median overall survival and durable responses in patients across selected tum...